LOS ANGELES, Nov. 28, 2022 (GLOBE NEWSWIRE) — RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services today reported that its lung artificial intelligence subsidiary, Aidence, and Google Health, a division of Alphabet, Inc. (NASDAQ: GOOG), announce an agreement to license Google Health’s AI research model for lung nodule malignancy prediction on CT imaging. Aidence will develop, validate and bring this model to the market to support the early and accurate diagnosis of lung cancer and the reduction of unnecessary procedures in screening programs.
Lung cancer screening with low-dose CT has been shown to significantly reduce lung cancer mortality by as high as 24% for men and 33% for women, according to the 2020 NELSON trial. Screening initiatives are increasingly being implemented in Europe, such as the UK’s Targeted Lung Health Checks. In the United States, eligibility criteria have recently been broadened, further reflecting the benefit of lung cancer screening.
A major difficulty in lung cancer screening is establishing the nature of detected lung nodules. Most of these nodules are not cancerous. However, properly identifying and diagnosing such nodules can be time-consuming, costly, anxiety-inducing for patients and their families and sometimes invasive, requiring follow-up CTs or surgical interventions.
Dr Raymond Osarogiagbon, Chief Scientist, Baptist Memorial Health Care Corporation and Director, Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee, explained, “One of the most exciting developments in contemporary population healthcare is the early detection of lung cancer. Unfortunately, the reality that most such nodules will be benign represents a real challenge that cries out for a technological solution. Artificial intelligence is one such solution.”
Dr Osarogiagbon continued, “The world looks forward to the rapid development and validation of software that will enhance our ability to find the many lung cancer needles in the giant haystack that is CT-detected lung nodules in today’s clinical practice.”
Deep learning, a subset of AI, has been shown to support the risk scoring of lung nodule malignancy. In a study published in Nature in 2018, scientists affiliated with Google Health presented a highly accurate model for malignancy classification, consistently matching the performance of experienced radiologists.
Aidence has also built a deep learning model for this purpose. Aidence’s algorithm successfully predicts lung cancer from a single scan and was awarded in the 2017 Kaggle challenge. Its robust performance was later confirmed in a clinical study comparing its performance to that of 11 radiologists on 300 cases.
Aidence and Google Health intend to complete an AI application for lung nodule malignancy prediction. In this collaboration, Google Health will provide its scientific expertise. Aidence will further develop the model into a solution for clinical practice and bring it to market, complying with relevant data privacy requirements and regulatory standards. The development of this AI application is a statement of intent and no regulatory market applications have been made and no orders for sale are being taken.
Outside of this collaboration with Google Health, Aidence has a proven track record of deploying AI in hospitals and clinics across Europe. Its application, Veye Lung Nodules, is currently running in over 80 routine practice and lung cancer screening sites.
Mark-Jan Harte, Aidence co-founder and CEO, said, “Our mission at Aidence is to give lung cancer patients a fighting chance. This strategic partnership with Google Health allows us to accelerate and expand our efforts toward achieving it.”
Mr. Harte continued, “We are enthusiastic about working on a powerful deep learning model for lung nodule malignancy prediction based on the work of the Aidence and Google teams, as well as making sure that all the other requirements that contribute to the successful deployment of AI in clinical practice are in place, like clinical validation, certification and integration into the clinical workflow.”
Akib Uddin, Product Manager at Google Health, commented, “At Google Health, we want to be an active, catalytic force in demonstrating the real-world benefits of AI in health. We know just how important lung cancer screening is in saving lives, and we are excited to play a role in driving impact at scale by enabling great partners like Aidence with our research.”
About RadNet, Inc.
RadNet, Inc., is the leading national provider of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 349 owned and/or operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida, Maryland, New Jersey and New York. Together with affiliated radiologists, inclusive of full-time and per diem employees and technologists, RadNet has a total of approximately 9,000 employees. For more information, visit http://www.radnet.com.
About Google Health
A division of Alphabet, Inc., Google Health is our company-wide effort to help billions of people be healthier. We work toward this vision by meeting people in their everyday moments and empowering them to stay healthy and partnering with care teams and the public health community to provide more accurate, accessible and equitable care. Our teams are applying our expertise and technology to improve health outcomes globally – with high-quality information and tools to help people manage their health and wellbeing, solutions to transform care delivery, research to catalyze the use of artificial intelligence for the screening and diagnosis of disease and data and insights to the public health community. https://health.google/
CONTACTS:
RadNet, Inc.
Mark Stolper, 310-445-2800
Executive Vice President and Chief Financial Officer
Related Quotes
Shares of clinical-stage biotechnology company Anavex Life Sciences (NASDAQ: AVXL) recently shot higher. Investors reacting to great news for its Alzheimer's disease drug candidate, blarcamesine, drove the stock about 40% higher when the market opened on Friday, Dec. 2. Is Anavex Life Sciences a smart stock to buy now, or will the road ahead be a rocky one full of potholes?
Wedbush on Friday launched coverage of Green Thumb Industries Inc. , Cresco Labs Inc. , Curaleaf Holdings Inc. and Trulieve Cannabis Corp. with outperform ratings. Analyst Gerald Pascarelli said of the four cannabis companies Green Thumb Industries ranks as Wedbush's top pick. "We believe that brighter days lie ahead for the U.S. cannabis industry and that incremental revenues from new states slated to come online for adult use sales, coupled with a normalization in trend in legacy markets, as w
Anavex Life Sciences said its experimental Alzheimer's treatment met the goals of a midstage study, leading AVXL stock to rocket early Friday.
Shares of Agenus (NASDAQ: AGEN) rose 12.5% on Friday. One big buyer was Values First Advisors, a financial advisory firm that bought 10,013 shares of the company and now owns 238,514 shares of Agenus. Agenus focuses on immuno-oncology therapies that boost the body's ability to fight cancer and infections by activating T-cell immune responses.
Cincinnati-based P&G will pay up to $8 million to settle a class action lawsuit over benzene in some of its Secret and Old Spice deodorant products.
Oncolytics Biotech (ONCY) receives a fast-track designation from the FDA for pelareorep combined with Roche's Tecentriq in advanced/metastatic pancreatic cancer indication.
The FDA approves Rigel's (RIGL) Rezlidhia (olutasidenib) for treating relapsed/refractory acute myeloid leukemia with a susceptible IDH1 mutation. Stock up.
Apparently cannabis is taking market share from alcohol. Cowen lists its favorite, pot and booze stocks.
Walking 10,000 steps a day is one of those mysteriously decided good things we should all do, much like drinking eight glasses of water a day. Evan Brittain, a cardiologist and associate professor at Vanderbilt University School of Medicine in Tennessee, co-wrote an October 2022 study published in Nature Medicine journal that measured how much exercise people actually got using Fitbit fitness trackers during a median of four years. “We looked across every human disease that showed up in unbiased analysis,” Brittain says.
When everyone around them stops taking pandemic precautions, it gets harder for immunocompromised Americans to protect themselves against COVID.
As healthcare costs continue to rise, more and more retailers are adding pharmacy and health services in new and creative ways. Heavy-hitting retailers like Walmart and Target have opened pharmacy departments to mixed results, while Dollar General's new CEO expressed interest in integrating healthcare services in its recent quarterly earnings call. Never a company to be left behind, Amazon has made moves to break into the healthcare industry.
Dead men do tell tales through their physical remains. AP Photo/Francesco BelliniThe previous pandemics to which people often compare COVID-19 – the influenza pandemic of 1918, the Black Death bubonic plague (1342-1353), the Justinian plague (541-542) – don’t seem that long ago to archaeologists. We’re used to thinking about people who lived many centuries or even millennia ago. Evidence found directly on skeletons shows that infectious diseases have been with us since our beginnings as a specie
By Faith Ashmore, Benzinga
Shares of Prometheus Biosciences (NASDAQ: RXDX) were down more than 12% this week as of Friday morning, according to data from S&P Global Intelligence. The clinical-stage biotech company specializes in immunotherapies with a focus on inflammatory bowel disease (IBD). Prometheus' lead therapy in its pipeline is IBD drug PRA023.
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Health officials have seen higher numbers of cases caused by Group A streptococci, bacteria that can cause respiratory and skin infections including strep throat, impetigo and scarlet fever.
The biotech reported positive results from a phase 2b/3 study of its lead Alzheimer's disease candidate.
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Interviews with hospital staff and a Kitsap Sun review of complaint records paint a concerning picture of the facility’s operations during that time.
Amgen stock dipped Thursday though the company unveiled promising results for its experimental obesity treatment.
Leave a Reply
You must be logged in to post a comment.